AstraZeneca reported victories on multiple fronts with its blood pressure drug baxdrostat, securing a second successful Phase 3 trial demonstrating efficacy in treatment-resistant hypertension using alternative measures. Concurrently, AstraZeneca and Daiichi Sankyo's antibody-drug conjugate Datroway extended survival in advanced triple-negative breast cancer, a population lacking immunotherapy options. These developments highlight AstraZeneca's expanding oncology and cardiovascular portfolios, potentially reshaping treatment paradigms for difficult-to-treat diseases.